Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: Implication of oxidative stress-PARP pathway

被引:58
作者
Jangra, Ashok [1 ]
Datusalia, Ashok Kumar [1 ]
Khandwe, Shriya [1 ]
Sharma, Shyam Sunder [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res, Mol Neuropharmacol Lab, Dept Pharmacol & Toxicol, Sas Nagar Mohali 160062, Punjab, India
关键词
Diabetes; Behavioral changes; Melatonin; Nicotinamide; Oxidative stress; PARP; NF-KAPPA-B; BRAIN ACETYLCHOLINESTERASE ACTIVITY; HIPPOCAMPAL NEUROGENESIS; COGNITIVE IMPAIRMENT; CELL-PROLIFERATION; MEMORY IMPAIRMENT; ACHE ACTIVITY; APOPTOSIS; INSULIN; MODEL;
D O I
10.1016/j.pbb.2013.10.021
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Diabetes associated hyperglycemia results in generation of reactive oxygen species which induces oxidative stress and initiate massive DNA damage leading to overactivation of poly (ADP-ribose) polymerase (PARP). In this study, we have elucidated the involvement of oxidative stress-PARP pathway using pharmacological interventions (melatonin, as an anti-oxidant and nicotinamide, as a PARP inhibitor) in diabetes-induced neuro-behavioral and neurochemical alterations. Sprague-Dawley rats were rendered diabetic by a single intraperitoneal injection of streptozotocin. Behavioral and cognitive deficits were assessed after 8 weeks of diabetes induction using a functional observation battery, passive avoidance and rotarod test. Acetylcholinesterase activity was significantly decreased in hippocampus of diabetic rats as compared to control rats. Diabetic animals showed significant increase in malondialdehyde levels and reduction in NAD levels in hippocampus. Glutamate and GABA levels were also altered in hippocampus of the diabetic animals. Two week treatment with melatonin (3 and 10 mg/kg) and nicotinamide (300 and 1000 mg/kg) alone and in combination significantly improved the neuro-behavioral parameters which were altered in diabetes. Neurotransmitter (glutamate and GABA) levels were improved by these interventions. Our results emphasize that simultaneous inhibition of oxidative stress-PARP overactivation cascade can be beneficial in treatment of diabetes associated CNS changes. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:43 / 51
页数:9
相关论文
共 77 条
[1]   Oxidative stress in neurodegeneration: cause or consequence? [J].
Andersen, JK .
NATURE MEDICINE, 2004, 10 (07) :S18-S25
[2]   N-benzoyl-D-phenylalanine attenuates brain acetylcholinesterase in neonatal streptozotocin-diabetic rats [J].
Ashokkumar, Natarajan ;
Pari, Leelavinothan ;
Ramkumar, Kunga Mohan .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 99 (03) :246-250
[3]   Prominently decreased hippocampal neurogenesis in a spontaneous model of type 1 diabetes, the nonobese diabetic mouse [J].
Beauquis, J. ;
Saravia, F. ;
Coulaud, J. ;
Roig, P. ;
Dardenne, M. ;
Homo-Delarche, F. ;
De Nicola, Alejandro .
EXPERIMENTAL NEUROLOGY, 2008, 210 (02) :359-367
[4]   Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment [J].
Beauquis, J ;
Roig, P ;
Homo-Delarche, F ;
De Nicola, A ;
Saravia, F .
EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (06) :1539-1546
[5]   Mental Health Issues in Adolescents and Young Adults With Type 1 Diabetes: Prevalence and Impact on Glycemic Control [J].
Bernstein, Carrie M. ;
Stockwell, Melissa S. ;
Gallagher, Mary Pat ;
Rosenthal, Susan L. ;
Soren, Karen .
CLINICAL PEDIATRICS, 2013, 52 (01) :10-15
[6]   Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment [J].
Biessels, GJ ;
Kamal, A ;
Urban, IJA ;
Spruijt, BM ;
Erkelens, DW ;
Gispen, WH .
BRAIN RESEARCH, 1998, 800 (01) :125-135
[7]   CEREBRAL FUNCTION IN DIABETES-MELLITUS [J].
BIESSELS, GJ ;
KAPPELLE, AC ;
BRAVENBOER, B ;
ERKELENS, DW ;
GISPEN, WH .
DIABETOLOGIA, 1994, 37 (07) :643-650
[8]   Cerebral dysfunction in type 1 diabetes: effects of insulin, vascular risk factors and blood-glucose levels [J].
Brands, AMA ;
Kessels, RPC ;
de Haan, EHF ;
Kappelle, LJ ;
Biessels, GJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 490 (1-3) :159-168
[9]  
Brioni JD, 2004, DRUG DEVELOP RES, V28, P3, DOI DOI 10.1002/DDR.430280103
[10]   Predictors of cognitive impairment in type 1 diabetes [J].
Brismar, Tom ;
Maurex, Liselotte ;
Cooray, Gerald ;
Juntti-Berggren, Lisa ;
Lindstrom, Per ;
Ekberg, Karin ;
Adner, Nils ;
Andersson, Sten .
PSYCHONEUROENDOCRINOLOGY, 2007, 32 (8-10) :1041-1051